|
|
 |
| |
|
Home > Financial Services > Stock Brokers > D.E. Shaw Securities, L.L.C
D.E. Shaw Securities, L.L.C
The D. E. Shaw group is a specialized investment and technology development firm whose activities center on various aspects of the intersection between technology and finance.
The Company headquartered located in New York, the D. E. Shaw group encompasses a number of closely related entities with approximately US $20 billion in aggregate capital. Activities range from computer based quantitative investment management to the development and financing of technology oriented business ventures, but is tied together by a common focus on the economic implications of technological innovation. Since its organization in 1988, the firm has earned an international reputation for financial innovation and technological leadership, and has been described as the most intriguing and mysterious force on Wall Street.
The D. E. Shaw group is a major participant in many of the world’s capital markets, trading stocks, bonds, futures, options, currencies, convertible securities, swaps, and a variety of other financial instruments issued by companies and governments in both the major industrialized nations and a number of emerging markets.
Drawing on the technological and financial expertise of its professional staff, the D. E. Shaw group seeks to make selected private equity investments within industries it believes are likely to be fundamentally transformed by the use of technology. Transactions have ranged from purely passive investments in existing ventures managed by outside entrepreneurs to start-up firms that were organized by and incubated within the D. E. Shaw organization.
The Company group’s first two technology venture investments reflected its conclusion, based on a considerable amount of technical and market research, that advanced computational techniques would ultimately have a major impact on the way chemists design molecules for use in pharmaceutical products, new materials, and other applications.
The D. E. Shaw group later assumed a major ownership position in Schrodinger, a spinoff of Caltech and Columbia University that has since attracted substantial funding from the federal government and a number of large pharmaceutical firms to support the commercial application of significant computational breakthroughs achieved by its founders within the fields of quantum chemistry, drug design, molecular modeling, and protein structure determination.
In 1998, the firm founded Attenuon, LLC, a San Diego based pharmaceutical company developing cancer therapeutics that works by selectively disrupting angiogenesis and metastasis. Based on this approach, Attenuon seeks to develop broad-spectrum cancer drugs that have fewer side effects, are more suitable for long-term use, and work in combination with existing therapies.
Financial Services Companies
all are here at FinancialBrowsers.com Permission is granted to reproduce this article as long as the above resource paragraph is left intact with active links.
Back to Stock Brokers
|
|
|
|
|
|
|